Japan: governmental supplementary expenditure for COVID-19 medical and pharmaceutical measures 2020

The Japanese government announced the supplementary budged related to the economic stimulus package concerning coronavirus disease (COVID-19) on April 20, 2020. A total expense of around 1.8 trillion Japanese yen was planned for medical and pharmaceutical related measures, 13.9 billion yen of which were for securing the antiviral drug Avigan (Favipiravir). Only 10 billion yen were for supporting the development of vaccines in the country, while close to 22 billion yen were prepared for supporting the development of vaccines internationally.

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated facts and figures page.

Breakdown of governmental supplementary budget for medical and pharmaceutical related measures against coronavirus disease (COVID-19) in Japan announced on April 20, 2020 (in billion Japanese yen)

Characteristic	Budget in billion Japanese yen
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

April 2020

More information

Region

Japan

Survey time period

April 20, 2020

Supplementary notes

*To be allocated for measures implemented by local governments regarding Emergency Economic Package, depending on circumstances.
**Includes grants for PCR screening devices, securing hospital beds and facilities for patients with slight symptoms, securing medical equipment, or assisting dispatch of supporting doctors, etc.
***Such as distributing masks to kindergartens, elementary schools, nursing homes, and other facilities.

100 Japanese yen equal 0.74 U.S. dollars or 0.70 euros as of December 2022.

Citation formats